Drug Profile
Dalantercept - Acceleron Pharma
Alternative Names: ACE-041; ALK1-Fc Fusion Protein ACE-041Latest Information Update: 01 Dec 2021
Price :
$50
*
At a glance
- Originator Acceleron Pharma
- Developer Acceleron Pharma; Gynecologic Oncology Group; National Cancer Institute (USA)
- Class Antineoplastics; Immunoglobulin fusion proteins
- Mechanism of Action ACVRL1 protein antagonists; Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Head and neck cancer
- Phase I/II Liver cancer
- No development reported Multiple myeloma; Solid tumours
- Discontinued Endometrial cancer; Renal cell carcinoma
Most Recent Events
- 22 Nov 2021 Acceleron Pharma has been acquired by Merck & Co
- 04 Nov 2017 No recent reports of development identified for phase-I development in Multiple-myeloma(Late-stage disease, Second-line therapy or greater) in USA (SC, Injection)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (SC, Injection)